Health, Criminal Justice, Human Rights

ISCTE–EMCDDA European Summer School on illicit drugs

2 - 13 July 2012 Lisbon, Portugal

The Lisbon-based Instituto Superior das Ciências do Trabalho e da Empresa (ISCTE) and the EU drugs agency (EMCDDA) are currently collaborating on a summer school programme entitled: ‘Illicit drugs in Europe: supply, demand and public policies’. Registration opens today for the course which will take place in Lisbon from 2–13 July 2012.

During the two-week course, EMCDDA scientific experts, ISCTE-professors and policymakers, will prepare participants to meet the complex policy challenges in this field, by providing a multi-disciplinary and inclusive approach to the study of the drug problem, both in Europe and beyond.

Week 1 of the summer school focuses on ‘Defining the problems’ and will feature lectures on ‘Problem drug use in Europe’, ‘Drug supply in Europe’ and ‘Detecting new drugs’.

Week 2 explores ‘Understanding drug policies and interventions’ with lectures on ‘(Inter)national drug policies’, ‘Preventing drug use’ and ‘Harm reduction’ and ‘Prison health’.

The target audiences for the summer school are university students (undergraduate and graduate), researchers, professionals and administrators interested or working in the drugs field.

ECTS credits will be given for the courses and students can transfer credits to other European universities using the ECTS-system.

Further information on the summer school programme, fees and location is available on the website.  


First phase: 15 December–15 March (discount for registration in this phase)

Second phase: 15 March–15 June

Limit: 50 participants

Applicants must send a completed application form, a CV and a proof of payment of the inscription fees to this address.  

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Related profiles

European Monitoring Centre on Drugs and Drug Addiction (EMCDDA)

The EMCDDA provides the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.

View profile

Supported by grants from

Open Society Foundations Robert Carr Fund

© 2020 International Drug Policy Consortium